Immune Therapy Toxicities Related to Breast Cancer Thyroid and adrenal insufficiency
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Immune Therapy Toxicities Related to Breast Cancer Thyroid and adrenal insufficiency at the 2018 Oncology ...
Author: moasc
Added: 03/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Continue to Refine Understanding of Biomarkers Find the right combinations with least toxicity
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares the Continuation to Refine Understanding of Biomarkers and Find the right combinations with least toxicity at the 2018 Oncol...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 7, 2018 Category: Cancer & Oncology Source Type: podcasts
ADD - What are the options for a myeloma patient who has relapsed on a two-drug combination?
In this weeks video, Dr. Brian G.M. Durie advises that patients discuss with their doctors the many aspects of various treatments, including possible toxicities, cost issues, the patients overall he...
Author: InternationalMyelomaFoundation
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
As our knowledge of immunotherapy increases, so has our understanding of its side effects. In this interview, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the types of imm...
Author: VJHemOnc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Echelon-1 Data Showed Modified Progression Free Survival Increased toxicity may not be worth a few points in overall survival
Elizabeth Brm, MD - HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Echelon-1 Data Showed Modified Progression Free Survival Increased toxicity may not be worth a few point...
Author: moasc
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Efficacy & Toxicity of CAR-T Trials and The Echelon-1 Trial Brentuximab Vedotin + AVD or ABVD
Elizabeth Brm, MD - HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Efficacy & Toxicity of CAR-T Trials and The Echelon-1 Trial Brentuximab Vedotin + AVD or ABVD at MOASCs...
Author: moasc
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Gluten-Free Diets: Healthy or Potentially Toxic?
Dr David Johnson on new data suggesting that these popular diets may lead to an accumulation of heavy metals. (Source: Medscape Gastroenterology Podcast)
Source: Medscape Gastroenterology Podcast - February 6, 2018 Category: Gastroenterology Authors: Medscape Source Type: podcasts
Toxicities with IDH1 & IDH2 Inhibitors - IDH Differentiation Syndrome is a new side-effect
Deepa Jeyakumar, MD, from UC Irvine Health For Multiple Myeloma Research joins us at MOASCs Spotlight On Hematology in Huntington Beach to discuss the toxicities with IDH1 & IDH2 inhibitors and a ne...
Author: moasc
Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 1, 2018 Category: Cancer & Oncology Source Type: podcasts
This Phase 3 Trial has Shown Improved Overall Survival - Toxicity Profile has been stable with prolonged exposure to drugs
Keith Stewart, MD from Mayo Clinic Division of Hematology and Oncology discusses this phase 3 trial has shown improved overall survival and toxicity profile has been stable with prolonged exposure to ...
Author: ASHReport
Added: 01/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Phase 2 Trials of BCMA Targeted Therapy - Find safety, toxicity, and efficacy in a larger patient population
Sagar Lonial, MD from Winship Cancer Institute of Emory University discusses phase 2 trials of BCMA targeted therapy and finding safety, toxicity, and efficacy in a larger patient population at the 20...
Author: ASHReport
Added: 01/23/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Who Should Get PRRT?
Soulen - Who Should Get PRRT Weighing Cumulative Toxicity Key to PRRT Treatment<br /><br />Michael C. Soulen, MD of the University of Pennsylvania answers the question "Who Should Get PRRT?". He summarizes th...
Author: AnnualMeetingGI2016
Added: 01/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 19, 2018 Category: Cancer & Oncology Source Type: podcasts
Risks of Toxicity with Interferon - Chronic low-grade toxicities with the therapy
Ruben Mesa, MD, from UT Health San Antonio Cancer Center discusses risks of toxicity with interferon and chronic low-grade toxicities with the therapy at the 2017 American Society of Hematology.
Author: ASHReport
Added: 01/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2018 Category: Cancer & Oncology Source Type: podcasts
Prophylactic treatment for CAR T-cell toxicity shows promising results
For CAR T-cell therapy to become mainstream, the management of related toxicities needs to be addressed. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in At...
Author: VJHemOnc
Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Cytokine storms: CAR T-cell hyperinflammatory response distinct from cytokine release syndrome?
Cytokine release syndrome (CRS) is a relatively well-described toxicity of CAR T-cell therapy. However, their may be delayed manifestations of CRS, such as disseminated intravascular coagulation (DIC)...
Author: VJHemOnc
Added: 01/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 5, 2018 Category: Cancer & Oncology Source Type: podcasts
Two Reasons Osimertinib in 1st Line Good Toxicity Profile & amp; Crossing Blood Brain Barrier
Anne S. Tsao, MD of MD Anderson Cancer Center discusses two reasons Osimertinib is good for first line treatment such as it's good toxicity profile and how it crosses the blood brain barrier from the ...
Author: thoraciconcology
Added: 12/29/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 29, 2017 Category: Cancer & Oncology Source Type: podcasts
